On the path to 2025: understanding the Alzheimer’s disease continuum
Paul Aisen(University of Southern California), Bruno Dubois(Portland State University), Brandy R. Matthews(Eli Lilly (United States)), Philip Scheltens(Amsterdam University Medical Centers), Roy Jones(Royal United Hospital), Jeffrey L. Cummings(University of California, Los Angeles), Joel Raskin(Eli Lilly (United Kingdom)), John C. Morris(Washington University in St. Louis), Lutz Frölich(Heidelberg University), Reisa A. Sperling(Harvard University), Sherie A. Dowsett(Eli Lilly (United States)), Clifford R. Jack(Mayo Clinic)
Cited by 559
Related Papers
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|18.9k
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k